Skip to main content
Top
Published in: International Journal of Clinical Oncology 6/2010

01-12-2010 | Original Article

Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East

Authors: Nobuaki Matsubara, Hirofumi Mukai, Shunji Nagai, Kuniaki Itoh

Published in: International Journal of Clinical Oncology | Issue 6/2010

Login to get access

Abstract

Background

Primary unknown cancer (PUC) is not rare neoplasm. The clinical features and survival time of these patients are heterogeneous. We analyzed cases that were referred to the National Cancer Center Hospital East with preliminary diagnosed PUC to evaluate the natural history and clinical features.

Methods

We retrospectively reviewed medical records of PUC patients who were referred to our institution between August 2005 and December 2008.

Results

One hundred and twenty-six patients with preliminary diagnoses of PUC were referred to the National Cancer Center Hospital East from community hospitals. The median age was 63 years (range 31–89 years). Almost all patients (85.7%) had good performance status (0–1). The mean interval between the first visit to a community hospital and referral to our hospital was 3.66 months (range 0–60 months). In 41 patients (32.5%), primary malignancies were identified by immunohistochemical studies and radiographical workup after referral to our hospital. Twenty-eight patients (22.2%) were defined as belonging to favorable subsets. About 50% of patients with unfavorable subsets received chemotherapy. None of the patients were autopsied.

Conclusion

In about half of the patients with preliminary diagnosed PUC, the primary origin could be identified, or it was possible to distinguish subsets with favorable prognosis.
Literature
2.
go back to reference Levi F, Te VC, Erler G et al (2002) Epidemiology of unknown primary tumours. Eur J Cancer 38:1810–1812PubMedCrossRef Levi F, Te VC, Erler G et al (2002) Epidemiology of unknown primary tumours. Eur J Cancer 38:1810–1812PubMedCrossRef
3.
go back to reference Nystrom JS, Weiner JM, Heffelfinger-Juttner J et al (1977) Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53–58PubMed Nystrom JS, Weiner JM, Heffelfinger-Juttner J et al (1977) Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53–58PubMed
4.
go back to reference Nystrom JS, Weiner JM, Wolf RM et al (1979) Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA 241:381–383PubMedCrossRef Nystrom JS, Weiner JM, Wolf RM et al (1979) Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA 241:381–383PubMedCrossRef
5.
go back to reference Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRef Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRef
6.
go back to reference Culine S, Kramar A, Saghatchian M et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683PubMedCrossRef Culine S, Kramar A, Saghatchian M et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683PubMedCrossRef
7.
go back to reference van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW et al (2002) Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer 38:409–413PubMedCrossRef van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW et al (2002) Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer 38:409–413PubMedCrossRef
8.
go back to reference Yakushiji S, Ando M, Yonemori K et al (2006) Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Int J Clin Oncol 11:421–425PubMedCrossRef Yakushiji S, Ando M, Yonemori K et al (2006) Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Int J Clin Oncol 11:421–425PubMedCrossRef
9.
go back to reference Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272–1280PubMed Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272–1280PubMed
10.
go back to reference Altman E, Cadman E (1986) An analysis of 1539 patients with cancer of unknown primary site. Cancer 57:120–124PubMedCrossRef Altman E, Cadman E (1986) An analysis of 1539 patients with cancer of unknown primary site. Cancer 57:120–124PubMedCrossRef
11.
go back to reference Milliken ST, Tattersall MH, Woods RL et al (1987) Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 23:1645–1648PubMedCrossRef Milliken ST, Tattersall MH, Woods RL et al (1987) Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 23:1645–1648PubMedCrossRef
12.
go back to reference Falkson CI, Cohen GL (1998) Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 55:116–121PubMedCrossRef Falkson CI, Cohen GL (1998) Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 55:116–121PubMedCrossRef
13.
go back to reference Eagan RT, Therneau TM, Rubin J et al (1987) Lack of value for cisplatin added to mitomycin–doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 10:82–85PubMedCrossRef Eagan RT, Therneau TM, Rubin J et al (1987) Lack of value for cisplatin added to mitomycin–doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 10:82–85PubMedCrossRef
14.
go back to reference NCCN Practice Guidelines for Occult Primary Tumors (1998) National Comprehensive Cancer Network. Oncology (Williston Park) 12:226–309 NCCN Practice Guidelines for Occult Primary Tumors (1998) National Comprehensive Cancer Network. Oncology (Williston Park) 12:226–309
15.
go back to reference Su AI, Welsh JB, Sapinoso LM et al (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61:7388–7393PubMed Su AI, Welsh JB, Sapinoso LM et al (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61:7388–7393PubMed
16.
go back to reference Bloom G, Yang IV, Boulware D et al (2004) Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 164:9–16PubMed Bloom G, Yang IV, Boulware D et al (2004) Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 164:9–16PubMed
17.
go back to reference Varadhachary GR, Talantov D, Raber MN et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442–4448PubMedCrossRef Varadhachary GR, Talantov D, Raber MN et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442–4448PubMedCrossRef
18.
go back to reference Mayordomo JI, Guerra JM, Guijarro C et al (1993) Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 79:321–324PubMed Mayordomo JI, Guerra JM, Guijarro C et al (1993) Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 79:321–324PubMed
19.
go back to reference Bugat R, Bataillard A, Lesimple T et al (2003) Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 89(Suppl 1):S59–S66PubMedCrossRef Bugat R, Bataillard A, Lesimple T et al (2003) Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 89(Suppl 1):S59–S66PubMedCrossRef
Metadata
Title
Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East
Authors
Nobuaki Matsubara
Hirofumi Mukai
Shunji Nagai
Kuniaki Itoh
Publication date
01-12-2010
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0112-3

Other articles of this Issue 6/2010

International Journal of Clinical Oncology 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine